New CEO to Focus on Enterprise-Level Transformation of Healthcare Industry Through Real World Evidence Solutions and AI Insights Platform
Boston, MA, January 7, 2019 – Concerto HealthAI, a technology leader in definitive Real World Data (RWD) and Artificial Intelligence solutions for precision health in oncology and other key therapeutic areas, and its Chief Executive Officer, Dr. Jeff Elton, will present at J.P Morgan’s exclusive meeting of investors, entrepreneurs and executives spanning the entire healthcare landscape, on January 8, 2019, at 2:30 p.m. in San Francisco, CA.
Concerto HealthAI is the emerging leader in integrated clinical RWD, AI solutions and outcomes science and has the largest and fastest-growing RWD oncology dataset in the market. Concerto HealthAI has an exclusive partnership with CancerLinQ, a non-profit subsidiary of the American Society of Clinical Oncology (ASCO). With CancerLinQ, Concerto HealthAI is bringing its clinical and technical expertise to collaborative research efforts with the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) to accelerate insights and understanding of the real-world use, tolerability, and effectiveness of immune checkpoint inhibitors.
Combined with its AI platform, eurekaHealth™, Concerto HealthAI’s data and analytics solutions support and streamline drug development, clinical trials, HEOR analytics, and improve patient outcomes. Concerto HealthAI is a leader in clinical outcomes research, HEOR, prospective real-world digital registries, and clinical development synthetic control arm studies – the forefront of Real-World Evidence solutions.
“At Concerto HealthAI, we are combining technology with RWD at a scale that has been unavailable to most healthcare organizations until now,” said Dr. Elton, the CEO of Concerto HealthAI. “This means a comprehensive – and accelerated – approach to generating insights, designing studies and finding patterns for precision medicine and improved patient outcomes that just isn’t possible in current clinical or scientific literature or practice.”
One such application of the eurekaHealth AI platform, presented at ASCO 2018, focused on side effects of chemotherapy in breast cancer patients. One in five breast cancer patients receiving chemo are susceptible to a life-threatening side-effect called neutropenia, where the immune system loses its ability to fight off infections. Leveraging eurekaHealth on a de-identified real-world dataset of 10,288 breast cancer patients, Concerto HealthAI’s platform demonstrated an average 27% increase in prediction of chemo-induced neutropenia compared to existing studies.
In September, Concerto HealthAI strengthened its leadership team with the appointment of Jeff Elton, Ph.D., as CEO. Dr. Elton brings over 25 years of experience in healthcare and life sciences and previously was Managing Director, Accenture Strategy & Predictive Health Intelligence, global COO of Novartis’ Institutes for BioMedical Research and a McKinsey partner in Pharmaceuticals & Medical Products. He is a founding board member and senior advisor to several early-stage biotechnology and AI companies and a member of the Massachusetts Biotechnology Council and Forbes Technology Council. Dr. Elton co-authored the groundbreaking book, “Healthcare Disrupted: Next Generation Business Models and Strategies.” Published in 2016, “Healthcare Disrupted” created an industry roadmap for AI, advanced analytics, real-world data, and digital medical solutions.
Concerto HealthAI is a portfolio company of SymphonyAI, a group of companies that provide leading AI-centric solutions for transforming the business enterprise for the retail, CPG, healthcare and industrial verticals. Founded by Dr. Romesh Wadhwani and backed with his $1 billion investment, SymphonyAI is one of the fastest growing companies in the business-to-business AI solutions sector with 1,500 employees.
“We are on the verge of a new age in healthcare and I’m thrilled to join Concerto HealthAI and guide this transformation that will greatly improve patient treatments and outcomes through the use of RWD and AI,” Dr. Elton said.